Inhibitors of the kynurenine pathway.
Strokes (intracranial thomboses or haemorrhaging) cause death and disability, but effective treatments are lacking. The metabolism of tryptophan leads to the generation of quinolinic acid, an agonist potentially neurotoxic at glutamate receptors, and kynurenic acid, an antagonist at the same population of receptors. The commercial development of the kynurenine pathway has included the use of analogues of kynurenic acid as antagonists at glutamate receptors. A second has been to use prodrugs of kynurenic acid or its analogues. Alternatively, it is proving possible to interfere directly with the kynurenine pathway to block the synthesis of quinolinic acid and promote the formation of kynurenic acid. This change yields neuroprotectant and anticonvulsant compounds.
Stone
T W
TW
Institute of Biomedical & Life Sciences, West Medical Building, University of Glasgow, Glasgow, UK. t.w.stone@bio.gla.ac.uk
D000818:Animals; D006801:Humans; D007737:Kynurenine / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000503:physiopathology
D007737:Kynurenine